News Headlines

  1. Avista Therapeutics And Forge Biologics Announce AAV Development And cGMP Manufacturing Partnership 8/13/2025

    Avista Therapeutics (“Avista”), a pre-clinical-stage biotechnology company developing novel AAV capsids with high efficacy and unique tropisms into innovative gene therapies for rare ophthalmic conditions, and Forge Biologics, (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to advance the development and manufacturing of AVST-101, Avista’s lead gene therapy candidate targeting X-linked retinoschisis (XLRS), a serious inherited retinal disease.

  2. BioDlink Accelerates Global Expansion With Bevacizumab Launch In Colombia And Pakistan 8/13/2025

    BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia's National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan's Drug Regulatory Authority of Pakistan (DRAP).

  3. Pace® Life Sciences Debuts Enhanced cGMP Manufacturing Capabilities To Support Increasing Demand For Sterile Injectables 8/12/2025

    Pace® Life Sciences, a U.S.-based CRDMO and full-service FDA-registered GMP Analytical Testing laboratory re-opened its 33,000 square foot facility in Salem, NH with advanced technologies to support small batch manufacturing.

  4. Lupin Announces Licensing Deal For Ranibizumab Biosimilar 8/12/2025

    Global Pharma major Lupin Limited (Lupin) today announced that it has partnered with Sandoz Group AG (Sandoz), Switzerland, to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions.

  5. Primo Biotech And Anbogen Therapeutics Forge Co-Develop Precision Radioligand For Solid Tumors Diagnosis And Therapy 8/12/2025

    Primo Biotechnology Co., Ltd., a pioneering developer of Radioligand Drug Conjugates (RDCs), announced today the signing of a Memorandum of Understanding (MoU) with AnBogen Therapeutics, Inc., a prominent biotech firm specializing in novel drug development.

  6. Bionova Scientific Opens New pDNA Facility In Texas To Support Rapidly Growing Biopharma Industry 8/12/2025

    Bionova Scientific, a full-service biologics contract development and manufacturing organization (CDMO) and subsidiary of global conglomerate Asahi Kasei, has announced the opening of a 10,000 square-foot state-of-the-art plasmid DNA (pDNA) development and production facility in The Woodlands, Texas.

  7. WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production At Pilot-Scale 8/12/2025

    Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale.

  8. Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing Of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology 8/12/2025

    Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. (AAVnerGene) platform technology.

  9. AbbVie Announces $195M Investment To Expand Active Pharmaceutical Ingredient Manufacturing In The U.S. 8/12/2025

    AbbVie (NYSE: ABBV) today announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S.

  10. Intas & Accord Signs Agreement To Acquire Prothya Biosolutions 8/11/2025

    Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium.